Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
More children die from brain cancer than from any other disease in the western world. Many anti-cancer drugs are unable to cross the blood-brain barrier to reach the tumor and certain genetic mutations in the tumor cells increase resistance to chemotherapeutics. The novel chemotherapeutic drug VAL-083 readily crosses the blood-brain barrier and accumulates in brain tumor tissues and has documented activity against pediatric brain tumors in historical clinical trials. VAL-083 has a distinct mechanism of action that enables it to overcome common chemo-resistances, as well as work synergistically with drugs of the topoisomerase inhibitor family. This project aims to identify topoisomerase inhibitors that display maximum synergy with VAL-083 in selected pediatric CNS tumors and examine the tolerability of these combinations. TO BE CONT’D
Mads Daugaard
Sudha Kotapalli
Del Mar Pharmaceuticals Ltd
Medicine
Pharmaceuticals
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.